Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell more than 13% on Thursday. The biotech company, which specializes in using tumor-infiltrating lymphocyte (TIL) therapies to fight cancer, has seen its shares drop by more than 25% so far this year, hitting a 52-week low of $4.41 on Thursday.
Iovance has seen its shares drop for three consecutive days. The real driver is that competitors Seagen and Genmab announced earlier this month positive top-line data from a phase 3 trial for Tivdak to treat recurrent or metastatic cervical cancer. That could hurt the chances for Iovance therapy Lifileucel getting approval to treat the same condition. Lifileucel is also being looked at to treat melanoma, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). In response to the news, Stifel Nicolaus downgraded its price target for Iovance from $27 to $26 on Wednesday.
The drop seems excessive considering that Lifileucel has a decent chance of getting approval to treat advanced melanoma. The Food and Drug Administration (FDA) recently accepted the company’s Biologics License Application (BLA) for Lifileucel and granted the drug priority review with a Prescription Drug User Fee Act (PDUFA) target date of Nov. 25.
As of the second quarter, Iovance reported $317.3 million in cash, enough, it said, to fund operations into the end of next year. The company had $200,000 in revenue, all from its purchase of cancer therapy Proleukin from Clinigen Limited in January, and it lost $106.5 million in the quarter, compared to a loss of $213.9 million in the same period last year.
10 stocks we like better than Iovance Biotherapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Iovance Biotherapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 11, 2023
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]